Counter-Terrorism Focus, Regulatory Reform Plans Will Impact CDRH
This article was originally published in The Silver Sheet
NEW FDA COUNTER-TERRORISM INITIATIVES are slated to receive the bulk of any funding increase in FY 2003, leaving little monies for already cash-strapped day-to-day operations. Despite an influx of new hires, the Bush Administration’s goal of a six-fold increase in import product examinations could constrain field efforts to maintain current manufacturer inspection levels. While FDA adjusts its mission focus, consolidation plans within both HHS and FDA are expected to create more streamlined and unified operations. In the midst of these changes, Congress is set to take up a package of medical device reform measures and HHS is reviewing recommendations to ease FDA administrative burdens
You may also be interested in...
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.